SCYNEXIS Revenue and Competitors

Location

$206.4M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • SCYNEXIS's estimated annual revenue is currently $14.7M per year.(i)
  • SCYNEXIS's estimated revenue per employee is $216,544
  • SCYNEXIS's total funding is $206.4M.

Employee Data

  • SCYNEXIS has 68 Employees.(i)
  • SCYNEXIS grew their employee count by -23% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$10.9M700%N/AN/A
#2
$0.9M6-14%N/AN/A
#3
$11.9M77-6%N/AN/A
#4
$106.8M49223%N/AN/A
#5
$1.4M929%N/AN/A
#6
$0.9M6200%N/AN/A
#7
$14.7M68-23%$206.4MN/A
#8
$492.2M146118%$568MN/A
#9
$2.5M160%N/AN/A
#10
$4.5M297%N/AN/A
Add Company

SCYNEXIS™ provides a full range of synthesis chemistry services to the life sciences industry, From Concept To Clinic™. We offer novel hit generation compounds, hit explosion, lead optimization and radiochemistry services as well as the production of clinical samples in our GMP facility. Every day, SCYNEXIS is demonstrating that our people and technology meet the challenges – and even reshape – today’s pharmaceutical discovery process. The result: our customers are receiving unparalleled speed and efficiency that revolutionize the limits imposed on today’s discovery chemistry lab. SCYNEXIS is increasing the productivity and speed of the pharmaceutical discovery process by removing the boundaries of the chemistry lab. By utilizing our patented MEDCHEM-FACTORY™ process and other proprietary technology platforms, SCYNEXIS is quickly emerging as a company with special expertise in the areas of hit explosion and lead optimization. Harnessing technology in ways never seen before in discovery labs, we are uniquely positioned to meet the specific needs of our customers by providing targeted, and timely, expertise that is tailored to individual projects.

keywords:Healthcare

$206.4M

Total Funding

68

Number of Employees

$14.7M

Revenue (est)

-23%

Employee Growth %

N/A

Valuation

N/A

Accelerator

SCYNEXIS News

2022-04-20 - SCYNEXIS Announces Positive Interim Data from Phase 3 ...

Ongoing FURI and CARES studies are a key component of the SCYNEXIS strategy to build ibrexafungerp into a broad antifungal franchise. SCYNEXIS...

2022-04-20 - Synexis' new data on vaginal yeast infection drug Brexafemme

Scynexis hit the market eight months ago with Brexafemme, a long-awaited upgrade in the treatment of vaginal yeast infection. Now the New Jersey drugmaker...

2022-04-20 - Scynexis builds out case for its antifungal in the hospitalized ...

The antifungal work at Scynexis is not abating. Looking to expand beyond its initial June 2021 nod for treating vaginal yeast infection,...

2021-06-03 - SCYNEXIS, INC. SCYNEXIS : Announces FDA Approval of BREXAFEMME (ibrexafungerp tablets) as the First and Only Oral Non-Azole Treatment for Vaginal Yeast Infections

JERSEY CITY, N.J. - SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant fungal infections, announced that the U.S. Food and Drug Administration (FDA) has approved BREXAFEMME (ibrexafungerp tablets), ...

2020-04-09 - SCYNEXIS Secures $10 Million in Financing

JERSEY CITY, N.J., April 09, 2020 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the sale of its 6.0% Senior Convertible Notes due 2026 for an agg ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$13.5M6810%N/A
#2
$17M7035%N/A
#3
$7.5M714%N/A
#4
$14.1M71-4%N/A
#5
$3.5M7113%N/A

SCYNEXIS Executives


NameTitle
Ivor MacleodChief Financial Officer
David AnguloChief Medical Officer
Christine CoyneChief Commercial Officer, SCYNEXIS
Marco TagliettiPresident & Chief Executive Officer
Lawrence HoffmanInterim Chief Financial Officer
Nkechi AzieVice President, Clinical Development and Medical Affairs
Rajeshwar MotheramSenior Vice President, Pharmaceutical Development And Supply Chain
Richard SleddVice President Marketing and Sales (interim CCO)
Glen ParkVice President, Regulatory Affairs and Quality Assurance
Marco TagliettiPresident & Chief Executive Officer
Nkechi AzieVice President Clinical Development and Medical Affairs